Periprocedural platelet inhibition with cangrelor in P2Y-inhibitor naïve patients with acute coronary syndromes - A matched-control pharmacodynamic comparison in real-world patients.

Background: Effective inhibition of platelet aggregation during PCI in high risk patients with ACS is of utmost importance. The new intravenous short acting P2Y-receptor inhibitor cangrelor is available for use in PCI-treated patients. We aimed to study platelet inhibition during treatment with cangrelor and transition phase with oral P2Y-receptor inhibitors in patients with acute coronary syndromes (ACS).